Download The Findit App

Share Your Posts On These Major Social Networks

Instatag Your Posts to Instagram Facebook + Twitter

News

MissionIR News - VistaGen Therapeutics (VSTA) Authorizes Letter of Intent with NIMH for NIH-Sponsored Phase 2 Study of AV-101 in Major Depressive Disorder

Atlanta 11/18/2014 8:00:00 PM

MissionIR would like to highlight VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company, focused on applying proprietary human pluripotent stem cell technology for drug rescue and cell therapy. Its Human Clinical Trials in a Test Tube is a pluripotent stem cell technology platform for predictive toxicology, drug development, and drug rescue.

In the company’s news,

VistaGen has signed a Letter of Intent to enter into a Cooperative Research and Development Agreement (CRADA) with the National Institute of Mental Health (NIMH), part of the National Institutes of Health (NIH), to collaborate on a NIMH-sponsored Phase 2 clinical study of VistaGen’s lead drug candidate, AV-101, in Major Depressive Disorder. The disorder is one of the most common in the U.S.

Both VistaGen and NIMH look to complete the CRADA next month and both commencing and completing the Phase 2 depression study in 2015.

AV-101, an oral, non-sedating, non-hallucinogenic, NMDA receptor (NMDAR) glycineB-site antagonist, is a new generation of fast-acting, glutamatergic antidepressants with potential to treat millions of depression patients who are ineffectively served by classic antidepressants. Published NIH placebo-controlled clinical trials show evidence that ketamine, a classic NMDAR channel blocker, produces rapid-onset antidepressant effects. However, intravenously administered clinical utility of ketamine and other NMDAR channel blockers has been badly limited by their potential for abuse and dissociative side effects. By regulating as opposed to blocking NMDAR, AV-101 potentially can achieve the rapid-onset antidepressant effects of ketamine and other classic NMDAR channel blockers – all without causing their serious side effects.

Dr. Carlos Zarate, Chief, Section on the Neurobiology and Treatment of Mood Disorders and Chief of the Experimental Therapeutics and Pathophysiology Branch at the NIH’s National Institute of Mental Health, is expected to be the Principal Investigator of the AV-101 Phase 2 depression study under the proposed Cooperative Research and Development Agreement.

VistaGen CEO, Shawn K. Singh noted, “Depression is a global public health concern, affecting over 350 million people worldwide, including millions in the U.S. We are pleased to be on a specific path headed toward extending our long-standing relationship with the NIH. Collaborating under the new CRADA will provide us and the NIMH with an important near term opportunity to make a major difference in the battle against depression.”

VistaGen is a clinical-stage biopharmaceutical company developing innovative medicine for depression, cancer and diseases and conditions involving the central nervous system. VistaGen’s lead drug candidate, AV-101, is a novel, potent, oral NMDAR glycineB-site antagonist entering Phase 2 clinical development focused on depression.

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

To sign up for The MissionIR Report, please visit http://MissionIR.com

To connect with MissionIR via Facebook, please visit http://Facebook.com/MissionIR

To connect with MissionIR via Twitter, please visit http://Twitter.com/MissionIR

Please read FULL disclaimer on the MissionIR website: http://Disclaimer.MissionIR.com

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.

More News

MissionIR News - International Stem Cell Corporation (ISCO) has a Place in the SAGE Encyclopedia of Stem Cell Research


Released On: 4/8/2016
Views: 3784

MissionIR News - eXp Realty International Corporation (EXPI) Attains Exclusive Rights to VirBELA Platform within Real Estate Industry


Released On: 4/7/2016
Views: 4530

MissionIR News - Moxian (MOXC): Social Media is a Necessity for Small Businesses Too


Released On: 3/31/2016
Views: 3502

MissionIR News - OurPet’s Company (OPCO) Reaches Favorable Settlement in Patent Infringement Case


Released On: 3/24/2016
Views: 2866

MissionIR News - Content Checked Holdings (CNCK) Reminds Us That You Are What You Eat


Released On: 3/17/2016
Views: 2414

MissionIR News - Oakridge Global Energy Solutions, Inc. (OGES) Promises Your Machine Will Start Every Time with its Lithium-Ion Battery


Released On: 3/11/2016
Views: 2236

MissionIR News - International Stem Cell Corp. (ISCO): Benefits of Stem Cells Outlined in Israel/California Collaboration


Released On: 3/4/2016
Views: 2556

MissionIR News - OurPet’s Company (OPCO) Adapting to a Constantly Changing Pet Products Industry with Innovation


Released On: 3/3/2016
Views: 2256

MissionIR News - Avoid Getting Poisoned with the Help of a Personal Food Taster from Content Checked Holdings (CNCK)


Released On: 2/23/2016
Views: 3603

MissionIR News - Oakridge Global Energy Solutions, Inc. (OGES) Ushering in a New Era in Battery Manufacturing


Released On: 2/12/2016
Views: 2588

MissionIR News - International Stem Cell Corp. (ISCO) Eyes Growth through Partnerships to Develop Therapeutic and Biomedical Products Worldwide


Released On: 2/10/2016
Views: 2306

MissionIR News - Torchlight Energy Resources, Inc. (TRCH) Moving Forward with Planning of Next Phase of Drilling on Orogrande Project


Released On: 2/9/2016
Views: 2457

MissionIR News - Content Checked Holdings, Inc. (CNCK) Updates Investors through Release of CEO’s Letter to Shareholders


Released On: 1/20/2016
Views: 4248

MissionIR News - International Stem Cell Corporation (ISCO) – Florey Clinical Service Agreement Expected to Deliver Results Later this Year


Released On: 1/14/2016
Views: 4711

MissionIR News - Moxian (MOXC) Announces Launch of New Subsidiary in Beijing


Released On: 1/5/2016
Views: 2960

MissionIR News - Elephant Talk Communications (ETAK) Initiates Restructuring of Global Business Operations with Executive and Board Appointments


Released On: 12/18/2015
Views: 9269

MissionIR News - International Stem Cell Corp. (ISCO) Has a Broad Pipeline of Targets


Released On: 12/9/2015
Views: 2712

MissionIR News - Oakridge Global Energy Solutions (OGES) is Flying High in the Drone Market


Released On: 12/3/2015
Views: 3153

Load More wait